A novel approach to target inflammatory diseases
A disruptive path: the TREM-1 biology
Innate immunity constitutes the first line of defense in reaction to microbial pathogens or tissue damage. Inotrem focuses its therapeutic efforts on the biology of TREM-1*, an immunoreceptor expressed on innate immune cells.
TREM-1 modulates inflammation and its engagement promotes a dysregulated, excessive, and prolonged immune response in acute and chronic inflammatory syndromes. Unlike most inflammation inhibitors that cause immune-suppression, the pharmacological control of TREM-1 presents a unique therapeutic aptitude: immuno-modulation. It allows to control the cause of immune dysregulation leading to harmful effects observed in patients, while restoring an appropriate inflammatory response.
Inotrem is targeting different therapeutic modalities:
- Acute inflammatory syndromes in the critical care setting which are caused by severe infections (septic shock, COVID-19) or major tissue injury (ischemia-reperfusion injury, polytraumatism)
- Chronic inflammatory processes observed in auto-immune diseases, fibrotic diseases and immuno-oncology.
* TREM-1: Triggering receptor expressed on myeloid cells-1 (protein).
Leverage the TREM-1 pathway opportunities
Inotrem’s proprietary technology platform develops therapeutic solutions derived from its knowledge of the TREM-1 pathway in a number of indications characterized by acute or chronic inflammatory symptoms.